Loading data for AUPH — first visit, this takes a few seconds.

Aurinia Pharmaceuticals Inc. (AUPH)

NasdaqGM: AUPH · Real-Time Price · USD

16.29

-0.19 (-1.15%)

At close: Sep 02, 2026, 6:03 PM

Alert

The price, the headline numbers and the latest news, in one place.

No data available

Bid	12.84
Market Cap	2.15B
Revenue (ttm)	312M
Net Income (ttm)	314M
	1.40
	2.28
	7.1
	15.18
P/B (ttm)	3.50
P/S (ttm)	6.92
Earnings Date	Nov 9, 2026

Ask	17.28
Volume	630,578
Avg. Volume (20D)	1,450,363
Open	16.44
Previous Close	16.48
Day's Range	16.26 - 16.47
52-Week Range	10.34 - 19.25
Analyst	n/a
Price Target	n/a
Dividends	n/a
Ex-Dividend Date	n/a

About AUPH

Aurinia Pharmaceuticals Inc., a biopharmaceutical company, engages in delivering therapies to people living with autoimmune diseases with high unmet medical needs in the United States and Japan. The company offers LUPKYNIS (voclosporin), an oral therapy for the treatment of adult patients with active lupus nephritis. It also develops aritinercept, a dual inhibitor of B cell-activating factor and proliferation-inducing ligand for the potential tre...

[Read more]

Industry Biotechnology

Sector Healthcare

IPO Date Sep 3, 2014

Employees 128

Stock Exchange NasdaqGM

Ticker Symbol AUPH

Website https://www.auriniapharma.com

Full Company Profile

Financial Performance

In 2025, Aurinia Pharmaceuticals's revenue was 283.06M, an increase of 20.38% compared to the previous year's 235.13M. Earnings were 287.2M, an increase of 4,893.08%.

Financial Statements

Earnings Surprise

Aurinia Pharmaceuticals has released their quarterly earnings on Aug 6, 2026:

Revenue of $83.22M misses estimates by $0, with 18.87% YoY growth.
EPS of 0.28 exceeds estimates by 0.04, with 75.00% YoY growth.

Next Earnings Release

Aurinia Pharmaceuticals Inc. is scheduled to release its earnings on Nov 9, 2026, before market opens.
Analysts project revenue of ... Upgrade

Why Price Moved

News

1 week ago · Insider Monkey

Could Aurinia Pharmaceuticals (AUPH) Stock Win Big After its LUPKYNIS Patent Settlement With Teva Pharmaceuticals (TEVA)?

Aurinia Pharmaceuticals Inc. (NASDAQ:AUPH) and Teva Pharmaceuticals Industries Limited (NYSE:TEVA) reached a major milestone on August 19, settling their U.S. patent dispute. Teva conceded that Aurini...

2 weeks ago · Simply Wall St.

How Investors Are Reacting To Aurinia Pharmaceuticals (AUPH) Extended Voclosporin Exclusivity And Share Buyback

Aurinia Pharmaceuticals Inc. recently reported second-quarter 2026 results showing higher revenue and earnings year over year, reiterated its 2026 revenue and net product sales guidance, completed a l...

2 weeks ago · Simply Wall St.

Aurinia Pharmaceuticals (AUPH) Stock Still Looks Cheap After A 74% Gain

Aurinia Pharmaceuticals stock has delivered a 74.2% return over the past three years, and the broader valuation checks currently lean toward the shares being on the cheap side rather than fully priced...

2 weeks ago · Stocktwits

AUPH Stock Rallies 6% After-Hours — Here’s Why

Aurinia said it and its U.S. subsidiary reached an agreement with Teva Pharmaceuticals resolving patent infringement litigation tied to Teva’s application to sell a generic version of LUPKYNIS.

1 month ago · Zacks

Aurinia Pharmaceuticals (AUPH) Surpasses Q2 Earnings Estimates

Aurinia (AUPH) delivered earnings and revenue surprises of +47.37% and -0.10%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Page 1 of 2

Aurinia Pharmaceuticals Inc. (AUPH)